|
|
|
LifeScienceHistory.com - Check us out on Instagram
Texas Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing TexasLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Cytori Azaya Therapeutics, Inc.
| | | Phone: | (210) 341-6600 | Fax: | (210) 341-6619 | Year Established: | 2003 | Main Contact: | Michael T. Dwyer, President & CEO | | Company Description | Azaya Therapeutics emerging biopharmaceutical company whose innovative technology platform allows it to make safer and more effective cancer treatments. Azaya utilizes a proprietary manufacturing process to produce liposome-encapsulated chemotherapeutics that eliminate the use of toxic carriers and incorporates a naturally occurring protein to stabilize the liposomal encapsulated drug. Azaya has leveraged its platform to develop a differentiated drug product for the global oncology market with docetaxel as its active ingredient. ATI-1123 is a patented human serum albumin-stabilized nanoparticle liposomal formulation of docetaxel and Azaya has completed Phase I clinical trials with this product. Docetaxel is available as a generic product and is also the active ingredient in Taxotere®. Docetaxel is one of the largest selling chemotherapy drugs in the world. Azaya is also developing a generic version of DOXIL/CAELYX, the first liposomal encapsulated chemotherapy drug approved by the FDA and the EMA.
On Feb. 15, 2017, Cytori announced the acquisition of certain assets from Azaya Therapeutics. Cytori’s aggregate commercialization milestone payment obligations to Azaya will not exceed $16.25 million, and its aggregate royalty payment obligations to Azaya based on product revenues will not exceed $100 million. | |
|
|
|
|
|